2025 Q4 -tulosraportti
UUTTA
2 päivää sitten1 t 3 min
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Määrä
Osto
800
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
33,91VWAP
Alin
32,35VaihtoMäärä
83,8 5 446 929
VWAP
Ylin
33,91Alin
32,35VaihtoMäärä
83,8 5 446 929
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q4 -tulosraportti | 28.1. | |
| 2025 Q3 -tulosraportti | 5.11.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 7.5.2025 | |
| 2024 Q4 -tulosraportti | 29.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenTeva-Q4 2025 - Comments Due to work, unfortunately, I don't have time to listen to the conference call directly, but it can be read within 24 hours on Teva's website and will be interesting to read. Looking at the share price development throughout the day, I must admit I am somewhat surprised. Pre-Market was quite down, probably -4%+ and here 0.5 hour before closing 1.5% up, a spread between USD 30.95 and 33.03, approx. USD 2, that's a lot, turnover well 16.3 million shares. One can ask oneself if the financial report was bad, nah, rather on the good side, is the future bad, nah, are there any price triggers in the future, yes, several, and here I'm mostly thinking about Duvakitung phase 3 results, where phase 2 results were far above expectation, here is a potential Blockbuster. Furthermore, there are several products in the early phase for market rollout, and if they continue at the same pace in 2026, yes, most of it will go to the bottom line, and that's something we like. Have been invested since 2019 and have had many, as in many shares, so I have reduced by 1/3 through 2025 as it went completely crazy, but plan to keep the rest for a while, but will probably reduce at USD 45 and USD 55, which I think will happen before the end of 2027, because I think dividends will become relevant in 2028 when the agreement, as I understand it, with the Israeli authorities expires at the end of 2027, and with dividends, the share will become interesting for funds that have stable healthcare stocks that pay dividends, and then demand will slowly but surely increase, as I'm sure funds have Teva on their radar.
·4 t sittenNo doubt it was a more obvious investment a couple of years ago. Now I see it more as slightly above average: TEVA's own goal is to increase free cash flow from $2.4 billion in 2025 to $3.5 billion in 2030. This corresponds to 8% annual growth. At the same time, they expect to reach debt/EBITDA of 2 in 2027 and will then potentially be able to return money to shareholders, so I immediately see an 8-10% annual return as realistic, as the current P/E of approx. 12 (I know Nordnet says 27 but they report an EPS of 2.65 when one does not include one-off incomes and has a share price of $33 which thus does not give 27) does not seem high. They can of course easily miss their targets but all in all, I still see a close to or slightly above market return with a slightly below market risk, as medicine is not the most volatile market and they are not dependent on a single blockbuster that risks being outcompeted by a better drug. I myself am up 215% and have not sold along the way but also started with a relatively small part of my portfolio invested in the company. I could sell but have other positions where I'd rather use the profit I can realize at a low tax rate, so I think I'll stay for now.·1 t sittenNow I write 8-10% return because I include the possibility the possibility of dividend (I am long-term so for me 2027 is not far into the future) and I write "close to or just above market return". That I would say 8-10% is. The historical average return has after all been 7-8%.- ·2 päivää sittenTeva Q4-2025: Press release found here: https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Innovative-Portfolio-and-Consistent-Execution-of-Pivot-to-Growth-Strategy-Deliver-Third-Consecutive-Year-of-Growth-Pipeline-Positioned-to-Unlock-Significant-Value-Potential/default.aspx Presentation: https://s24.q4cdn.com/720828402/files/doc_financials/2025/q4/Q4-2025-Earnings-Presentation.pdf Immediately it looks decent, better than expected, but let's see if the market agrees, See no need to sell, am heavily loaded in the stock (largest potion) and long-term.
·2 päivää sittenSame here, loaded up most of it 2018-21 and filled the last in April. Have patiently waited for the journey upwards and believe there is potential towards 45 USD within 2027. Too bad the dollar exchange rate is working against one. - ·22.1.Are there expectations for the financial report?·2 päivää sittenExpectations for the company have already risen as the company delivers according to plan. I hope and believe in continued stability and good growth in innovative products such as Austedo, Ajovy and Uzedy.
15.1.15.1.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
2 päivää sitten1 t 3 min
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenTeva-Q4 2025 - Comments Due to work, unfortunately, I don't have time to listen to the conference call directly, but it can be read within 24 hours on Teva's website and will be interesting to read. Looking at the share price development throughout the day, I must admit I am somewhat surprised. Pre-Market was quite down, probably -4%+ and here 0.5 hour before closing 1.5% up, a spread between USD 30.95 and 33.03, approx. USD 2, that's a lot, turnover well 16.3 million shares. One can ask oneself if the financial report was bad, nah, rather on the good side, is the future bad, nah, are there any price triggers in the future, yes, several, and here I'm mostly thinking about Duvakitung phase 3 results, where phase 2 results were far above expectation, here is a potential Blockbuster. Furthermore, there are several products in the early phase for market rollout, and if they continue at the same pace in 2026, yes, most of it will go to the bottom line, and that's something we like. Have been invested since 2019 and have had many, as in many shares, so I have reduced by 1/3 through 2025 as it went completely crazy, but plan to keep the rest for a while, but will probably reduce at USD 45 and USD 55, which I think will happen before the end of 2027, because I think dividends will become relevant in 2028 when the agreement, as I understand it, with the Israeli authorities expires at the end of 2027, and with dividends, the share will become interesting for funds that have stable healthcare stocks that pay dividends, and then demand will slowly but surely increase, as I'm sure funds have Teva on their radar.·4 t sittenNo doubt it was a more obvious investment a couple of years ago. Now I see it more as slightly above average: TEVA's own goal is to increase free cash flow from $2.4 billion in 2025 to $3.5 billion in 2030. This corresponds to 8% annual growth. At the same time, they expect to reach debt/EBITDA of 2 in 2027 and will then potentially be able to return money to shareholders, so I immediately see an 8-10% annual return as realistic, as the current P/E of approx. 12 (I know Nordnet says 27 but they report an EPS of 2.65 when one does not include one-off incomes and has a share price of $33 which thus does not give 27) does not seem high. They can of course easily miss their targets but all in all, I still see a close to or slightly above market return with a slightly below market risk, as medicine is not the most volatile market and they are not dependent on a single blockbuster that risks being outcompeted by a better drug. I myself am up 215% and have not sold along the way but also started with a relatively small part of my portfolio invested in the company. I could sell but have other positions where I'd rather use the profit I can realize at a low tax rate, so I think I'll stay for now.·1 t sittenNow I write 8-10% return because I include the possibility the possibility of dividend (I am long-term so for me 2027 is not far into the future) and I write "close to or just above market return". That I would say 8-10% is. The historical average return has after all been 7-8%.
- ·2 päivää sittenTeva Q4-2025: Press release found here: https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Innovative-Portfolio-and-Consistent-Execution-of-Pivot-to-Growth-Strategy-Deliver-Third-Consecutive-Year-of-Growth-Pipeline-Positioned-to-Unlock-Significant-Value-Potential/default.aspx Presentation: https://s24.q4cdn.com/720828402/files/doc_financials/2025/q4/Q4-2025-Earnings-Presentation.pdf Immediately it looks decent, better than expected, but let's see if the market agrees, See no need to sell, am heavily loaded in the stock (largest potion) and long-term.·2 päivää sittenSame here, loaded up most of it 2018-21 and filled the last in April. Have patiently waited for the journey upwards and believe there is potential towards 45 USD within 2027. Too bad the dollar exchange rate is working against one.
- ·22.1.Are there expectations for the financial report?·2 päivää sittenExpectations for the company have already risen as the company delivers according to plan. I hope and believe in continued stability and good growth in innovative products such as Austedo, Ajovy and Uzedy.
- 15.1.15.1.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
800
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
33,91VWAP
Alin
32,35VaihtoMäärä
83,8 5 446 929
VWAP
Ylin
33,91Alin
32,35VaihtoMäärä
83,8 5 446 929
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q4 -tulosraportti | 28.1. | |
| 2025 Q3 -tulosraportti | 5.11.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 7.5.2025 | |
| 2024 Q4 -tulosraportti | 29.1.2025 |
2025 Q4 -tulosraportti
UUTTA
2 päivää sitten1 t 3 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q4 -tulosraportti | 28.1. | |
| 2025 Q3 -tulosraportti | 5.11.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 7.5.2025 | |
| 2024 Q4 -tulosraportti | 29.1.2025 |
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenTeva-Q4 2025 - Comments Due to work, unfortunately, I don't have time to listen to the conference call directly, but it can be read within 24 hours on Teva's website and will be interesting to read. Looking at the share price development throughout the day, I must admit I am somewhat surprised. Pre-Market was quite down, probably -4%+ and here 0.5 hour before closing 1.5% up, a spread between USD 30.95 and 33.03, approx. USD 2, that's a lot, turnover well 16.3 million shares. One can ask oneself if the financial report was bad, nah, rather on the good side, is the future bad, nah, are there any price triggers in the future, yes, several, and here I'm mostly thinking about Duvakitung phase 3 results, where phase 2 results were far above expectation, here is a potential Blockbuster. Furthermore, there are several products in the early phase for market rollout, and if they continue at the same pace in 2026, yes, most of it will go to the bottom line, and that's something we like. Have been invested since 2019 and have had many, as in many shares, so I have reduced by 1/3 through 2025 as it went completely crazy, but plan to keep the rest for a while, but will probably reduce at USD 45 and USD 55, which I think will happen before the end of 2027, because I think dividends will become relevant in 2028 when the agreement, as I understand it, with the Israeli authorities expires at the end of 2027, and with dividends, the share will become interesting for funds that have stable healthcare stocks that pay dividends, and then demand will slowly but surely increase, as I'm sure funds have Teva on their radar.·4 t sittenNo doubt it was a more obvious investment a couple of years ago. Now I see it more as slightly above average: TEVA's own goal is to increase free cash flow from $2.4 billion in 2025 to $3.5 billion in 2030. This corresponds to 8% annual growth. At the same time, they expect to reach debt/EBITDA of 2 in 2027 and will then potentially be able to return money to shareholders, so I immediately see an 8-10% annual return as realistic, as the current P/E of approx. 12 (I know Nordnet says 27 but they report an EPS of 2.65 when one does not include one-off incomes and has a share price of $33 which thus does not give 27) does not seem high. They can of course easily miss their targets but all in all, I still see a close to or slightly above market return with a slightly below market risk, as medicine is not the most volatile market and they are not dependent on a single blockbuster that risks being outcompeted by a better drug. I myself am up 215% and have not sold along the way but also started with a relatively small part of my portfolio invested in the company. I could sell but have other positions where I'd rather use the profit I can realize at a low tax rate, so I think I'll stay for now.·1 t sittenNow I write 8-10% return because I include the possibility the possibility of dividend (I am long-term so for me 2027 is not far into the future) and I write "close to or just above market return". That I would say 8-10% is. The historical average return has after all been 7-8%.
- ·2 päivää sittenTeva Q4-2025: Press release found here: https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Innovative-Portfolio-and-Consistent-Execution-of-Pivot-to-Growth-Strategy-Deliver-Third-Consecutive-Year-of-Growth-Pipeline-Positioned-to-Unlock-Significant-Value-Potential/default.aspx Presentation: https://s24.q4cdn.com/720828402/files/doc_financials/2025/q4/Q4-2025-Earnings-Presentation.pdf Immediately it looks decent, better than expected, but let's see if the market agrees, See no need to sell, am heavily loaded in the stock (largest potion) and long-term.·2 päivää sittenSame here, loaded up most of it 2018-21 and filled the last in April. Have patiently waited for the journey upwards and believe there is potential towards 45 USD within 2027. Too bad the dollar exchange rate is working against one.
- ·22.1.Are there expectations for the financial report?·2 päivää sittenExpectations for the company have already risen as the company delivers according to plan. I hope and believe in continued stability and good growth in innovative products such as Austedo, Ajovy and Uzedy.
- 15.1.15.1.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
800
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
33,91VWAP
Alin
32,35VaihtoMäärä
83,8 5 446 929
VWAP
Ylin
33,91Alin
32,35VaihtoMäärä
83,8 5 446 929
Välittäjätilasto
Dataa ei löytynyt